The abstract is read at the publisher; the summary is JClub's.
Antifungal MICs are not self-interpreting for invasive fungal infections because clinical outcomes depend on species, testing thresholds, exposure, infection site, burden, and host factors.
- Why it matters: Susceptible in vitro results can still fail when non-classic phenotypes like tolerance, heteroresistance, persistence, trailing or paradoxical growth, and biofilm survival weaken the MIC–outcome link.
- What they did: The Personal View proposes treating antifungal susceptibility testing as a shared clinical-laboratory interface, with microbiologists defining organism, method, interpretive threshold, confidence, and confirmation, and clinicians integrating pharmacokinetics/pharmacodynamics, site, source control, toxicity, interactions, and trajectory.
- The result: Structured reporting—moving from isolated MICs to interpretation, uncertainty flags, and guidance—can improve stewardship, surveillance, and patient decisions while avoiding overconfident susceptible–resistant categorization when evidence is incomplete.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.